Antibody-drug conjugate 2 articles

A focus on monoclonal antibody targeting moiety separates antibody-drug conjugate from adjacent concepts and identifies it as a targeted antibody-payload therapeutic modality. From implementation to interpretation, cytotoxic payload delivery and cleavable linker chemistry describe the core process, whereas noncleavable linker chemistry and target-mediated cellular internalization define how the result is used. An ADC differs from an unconjugated monoclonal antibody because target recognition is coupled to a linked payload whose delivery and release are central to the drug’s mechanism.